biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 3/2024 | 20-02-2024 | Rozpoczęcie w drugim ośrodku testów systemu BacterOMIC w ramach Early Access Program

Previous PostNext Post

Related Posts

15.10.2026

Edocera develops device prototype and confirms its ability to detect signs of stroke

0
30.09.2026

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

0
28.09.2026

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations

0